Picture of Baseline Productions logo

BSSP Baseline Productions Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-1.54%
3m-2.62%
6m-9.44%
1yr-16.07%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-99%
50d MA-79.84%
200d MA-99.25%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Baseline Productions EPS forecast chart

Profile Summary

Baseline Productions, Inc., formerly Cantech Holding, Inc., is a development-stage immunotherapeutic-based technology company. The Company is focused on commercialization of its proteins for the treatment of cancer and various infectious diseases. Its Irreversible Pepsin Fraction (IPF) is a therapeutic platform technology that can be used to facilitate a range of applications. IPF turns on the immune system to fight autoimmune diseases. IPF binds to thymus (T)-cells and turns on T helper cell type 1 (Th1) immune system responses that kill infected cells. The Company's lead compound is a suspension of IPF, which is indicated for the treatment of autoimmune diseases, such as cancer, cirrhosis and Hepatitis C. The Company's product, IMMUNE-THERAPEUTIC PROTEIN (ITP), is a therapeutic protein isolated from porsine pepsin, which is irreversible, modified, and fractionate to the sequence IPF.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2015
Incorporated
September 27th, 2021
Public Since
September 28th, 2011
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
4,107,559,703

BSSP Share Price Performance

Similar to BSSP

Picture of Acorda Therapeutics logo

Acorda Therapeutics

us flag iconPink Sheets on Nasdaq

Picture of Actavia Life Sciences logo

Actavia Life Sciences

us flag iconPink Sheets on Nasdaq

Picture of Acura Pharmaceuticals logo

Acura Pharmaceuticals

us flag iconPink Sheets on Nasdaq

Picture of Adhera Therapeutics logo

Adhera Therapeutics

us flag iconPink Sheets on Nasdaq

Picture of Ramoil Management logo

Ramoil Management

us flag iconPink Sheets on Nasdaq

FAQ